title: Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences' by Shah.
authors.affiliation: Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
authors.affiliation: Institute of Rheumatology, Prague, Czech Republic.
authors.forename: Jiří
authors.initials: J
authors.lastname: Vencovský
authors.affiliation: Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
authors.forename: Jeehoon
authors.initials: J
authors.lastname: Ghil
authors.affiliation: Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
authors.forename: Jung Won
authors.initials: JW
authors.lastname: Kang
mesh_terms: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D000068800:Etanercept; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D059451:Biosimilar Pharmaceuticals; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept
keywords: Disease Activity; Inflammation; Treatment